ZyVersa Therapeutics Inc. (ZVSA) - Total Assets
Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) holds total assets worth $1.04 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ZVSA operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
ZyVersa Therapeutics Inc. - Total Assets Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See ZVSA total equity for net asset value and shareholders' equity analysis.
ZyVersa Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
ZyVersa Therapeutics Inc.'s total assets of $1.04 Million consist of 8.3% current assets and 91.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.65 Million | 90.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZVSA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ZyVersa Therapeutics Inc.'s current assets represent 8.3% of total assets in 2024, a decrease from 49.5% in 2020.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 25.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 90.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 90.5% of total assets.
ZyVersa Therapeutics Inc. Competitors by Total Assets
Key competitors of ZyVersa Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
ZyVersa Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.03 | 0.00 |
| Quick Ratio | 0.08 | 0.03 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-11.77 Million | $-11.15 Million | $-228.77K |
ZyVersa Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between ZyVersa Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.21 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -6.9% |
| Total Assets | $20.60 Million |
| Market Capitalization | $817.69K USD |
Valuation Analysis
Below Book Valuation: The market values ZyVersa Therapeutics Inc.'s assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ZyVersa Therapeutics Inc.'s assets decreased by 6.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual total assets of ZyVersa Therapeutics Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $20.60 Million | -6.85% |
| 2023-12-31 | $22.11 Million | -81.34% |
| 2022-12-31 | $118.51 Million | +10422.91% |
| 2021-12-31 | $1.13 Million | +64.27% |
| 2020-12-31 | $685.57K | -- |
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more